Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06538870 · ClinicalTrials.gov registry record · NA
Dental Implant Healing With TNF-Alpha Inhibitors
A NA study of Edentulism and Dental Implants, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06538870: Recruiting NA study of Edentulism and Dental Implants, sponsored by University of Pennsylvania.
NCT06538870 is a NA study of Edentulism and Dental Implants that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 30 participants, below the 187-participant average among 4 other Edentulism trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06538870, a NA study of Edentulism and Dental Implants, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to learn about healing after dental implant placement in patients taking a class of biologic drug called Tumor Necrosis Factor or TNF-alpha antagonist or inhibitor. The main questions it aims to answer are: Do patients taking TNF-alpha inhibitors have any complications after the placement of dental implants? Do patients taking TNF-alpha inhibitor experience increased pain after dental implant placement compared to the expected levels when healing from this procedure? Researchers will recruit patients both taking these drugs and those not taking these drugs to compare the outcomes between the two groups. Participants missing teeth will be recruited to receive dental implants to meet ideal dental status and will be followed before and after the implant placement to determine levels of health and ensure proper healing. Participants will be followed for a total of one year and follow up visits will consist of both clinical examination and radiographs (x-rays) to evaluate bone level and implant status. Participants will also be asked to rate their pain during clinic visits and at home on a diary and record the amount of pain control medication they take after the implant procedure.
Primary Outcome
A pilot cohort of patients will be recruited who require implants for standard of care restoration for tooth loss. Patients will be evaluated pre- and post-operatively and followed for 1 year to assess healing using clinical exam.
Conditions Studied
Interventions
- PROCEDURE Placement of dental implants
Study Locations (1)
Pennsylvania
- University of Pennsylvania School of Dental Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-28 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06538870 shows while recruiting
NCT06538870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 187-participant average among 4 other Edentulism trials with a reported enrollment target (84% lower).
The record links to 3 conditions, with Edentulism appearing as the primary indexed condition, and to 1 intervention - of which Placement of dental implants is the first listed.
NCT06538870 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06538870 about?
NCT06538870 is a clinical study titled "Dental Implant Healing With TNF-Alpha Inhibitors". The goal of this pilot study is to learn about healing after dental implant placement in patients taking a class of biologic drug called Tumor Necrosis Factor or TNF-alpha antagonist or inhibitor. The main questions it aims to answer are: Do patients taking TNF-alpha inhibitors have any complicatio...
What is the current status of trial NCT06538870?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-28. Estimated completion is 2026-12.
What conditions does trial NCT06538870 study?
This clinical trial studies the following conditions: Edentulism, Dental Implants, TNF-alpha Inhibitors.
What interventions are being tested in trial NCT06538870?
The interventions under investigation include: Placement of dental implants (PROCEDURE).
Who is sponsoring clinical trial NCT06538870?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06538870 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Edentulism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Platelet-Rich Fibrinogen in Extraction Socket Healing of the Aged
RECRUITING · NA
-
Study to Evaluate an Implant With a Sloped Top in Patients With a Sloped Jaw Bone
COMPLETED · NA
-
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
RECRUITING
-
Success Rate of Immediately Loaded Implants With Platform Switched Design Placed in Anterior Part of Mandible and Restored With Fixed Prostheses
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI